Rising Stroke Incidence Driving Growth in the Cerebrovascular Diseases Treatment Market to $10.1 Billion by 2035

Cerebrovascular diseases treatment market was valued at $5.8 billion in 2025 and is expected to grow to $10.1 billion by 2035, reflecting a CAGR of 5.8% over the 2026–2035 forecast period. The increasing prevalence of stroke globally is a central driver of growth in the cerebrovascular diseases treatment market. Stroke remains one of the most serious health challenges worldwide, imposing a growing need for effective therapeutic interventions across ischemic and hemorrhagic stroke types, as well as both medication and surgical treatment segments. The sheer number of people affected and the corresponding rise in long-term disability have heightened demand for advanced medical solutions, from clot?dissolving drugs and antiplatelet therapies to surgical procedures and post?acute care pathways.

Browse the full report description of “Cerebrovascular Diseases Treatment Market Size, Share & Trends Analysis Report by Type of Stroke (Ischemic, and Hemorrhagic), by Treatment (Medication, and Surgical Procedure), by End User (Hospitals, Surgical Clinics, and Research Institutes) Forecast Period, (2026-2035)” of https://www.omrglobal.com/industry-reports/cerebrovascular-diseases-treatment-market

Recent data strongly support this trend. According to the Centers for Disease Control and Prevention, more than 795,000 people experience a stroke each year in the US, with approximately 610,000 cases classified as first-time events. Ischemic strokes account for about 87% of all stroke cases, underscoring the dominance of medication-based treatment demand. In parallel, the World Stroke Organization Global Stroke Fact Sheet 2025 reports that 53% of adults globally live with at least one stroke risk factor, while 17% of stroke survivors experience recurrent events. Together, these figures highlight the persistent and growing need for comprehensive cerebrovascular disease treatment across prevention, acute intervention, and long-term management.

Cerebrovascular Diseases Treatment Market: Key Approvals, Partnerships, Innovations

• In March 2025, Genentech, part of Roche, announced FDA approval of TNKase (tenecteplase) for treating acute ischemic stroke (AIS) in adults. This marks their second FDA-approved stroke treatment, alongside Activase® (alteplase), highlighting their commitment to advancing stroke care.

• In August 2024, Pharmazz, Inc. partnered with Sun Pharmaceutical Industries to advance Sovateltide, a drug for acute cerebral ischemic stroke. Sun Pharma will invest $15 million in two installments to fund the Phase 3 trial in the US.

• In February 2024, CERENOVUS, part of Johnson & Johnson MedTech, launched the CEREGLIDE 71 Intermediate Catheter, designed for revascularizing acute ischemic stroke patients. This next-gen catheter features TruCourse technology and is optimized for direct aspiration and delivering compatible stent retrievers like EMBOTRAP III.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Type of Stroke
  • Treatment
  • End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – Abbott Laboratories, Boston Scientific Corp., Johnson & Johnson, Medtronic plc, Stryker Corp., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Cerebrovascular Diseases Treatment Market Report Segment

By Type of Stroke

• Ischemic
• Hemorrhagic

By Treatment

• Medication
• Surgical Procedure

By End-User

• Hospitals
• Surgical Clinics
• Research Institutions

Global Cerebrovascular Diseases Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

 To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/cerebrovascular-diseases-treatment-market